overall survival
FIG 1. · Panel OS_in_the_ITT_population
Panel OS_in_the_ITT_population 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
John F R Robertson, Zhimin Shao, Shinzaburo Noguchi, Igor Bondarenko, Lawrence Panasci, Sandeep Singh, Shankar Subramaniam, Matthew J Ellis
J Clin Oncol 43(13) 1539-1545
The randomized phase III FALCON trial demonstrated significant improvement in progression-free survival (PFS) with fulvestrant versus anastrozole in postmenopausal women with endocrine therapy-naïve, hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Herein, the prespecified final overall survival (OS) analysis is reported. After the primary PFS analysis, data were collected on survival, serious adverse events, and health-related quality of life. The final OS analysis was triggered at ≥65% maturity and ≥8 years since the last patient was enrolled. Analyses were descriptive with nominal P values (one-sided α threshold .01845). At the data cutoff (July 11, 2022), 314 (68.0%) of 462 patients had died (fulvestrant, 157/230 [68.3%], anastrozole, 157/232 [67.7%]). The final OS analysis of FALCON demonstrated no significant difference between fulvestrant and anastrozole (medians, 44.8 and 42.7 months, respectively; hazard ratio [HR], 0.97 [95% CI, 0.77 to 1.21]; P = .7579). Among patients with nonvisceral disease (n = 208), a trend showed a 15% reduction in the relative risk of death with fulvestrant versus anastrozole (median OS, 65.2 v 47.8 months; HR, 0.85 [95% CI, 0.60 to 1.20]). Data from FALCON are consistent with published evidence of long-term clinical benefit with fulvestrant and other endocrine therapies in the subset of patients with nonvisceral disease.
2 个 Figure · 5 个 KM 面板
FIG 1. Kaplan-Meier curve for OS in the ITT population. a HR (fulvestrant:anastrozole) <1 favors fulvestrant. Crosses represent censored observations. HR, hazard ratio; ITT, intention-to-treat; mOS, median OS; OS, overall survival. b Two-sided P value.
FIG 1. · Panel OS_in_the_ITT_population
Panel OS_in_the_ITT_population 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 2. OS in patients with (A) nonvisceral or (B) visceral disease a and exploratory analysis in patients with nonvisceral and visceral disease a in the (C) fulvestrant and (D) anastrozole arms. a Visceral disease was defined by the presence of tumors in the adrenal glands, bladder, CNS, esophagus, liver, lung, peritoneum, pleura, kidney, small bowel, stomach, pancreas, thyroid, colon, rectum, ovary, biliary tract, or spleen or by the presence of ascites, or pericardial or pleural effusion. b HR (fulvestrant:anastrozole) <1 favors fulvestrant. Crosses represent censored observations. Data cutoff: July 11, 2022. HR, hazard ratio; mOS, median OS; OS, overall survival.
FIG 2. · Panel A
Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 2. · Panel B
Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 2. · Panel C
Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 2. · Panel D
Panel D 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。